P1.21. Radiomic Signature of Identifies Outcome and Prognosis to Immune Checkpoint Inhibitors (ICI) in PD-L1 Low Non-small Cell Lung Cancer (NSCLC) - PDF(Slides)
Back to course
Pdf Summary
Asset Subtitle
Nathaniel Braman
Meta Tag
Speaker Nathaniel Braman
Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology
Keywords
retrospective study
AI-powered tool
PD-L1 negative NSCLC
immune checkpoint inhibitors
radiomic features
Cox proportional hazards model
progression-free survival
radiomic risk score
validated biomarkers
personalized medicine approaches
Powered By